# Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

> **NCT06532539** · PHASE2 · RECRUITING · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 30 (estimated)

## Conditions studied

- Endometrial Neoplasms
- Neoplasm Recurrence, Local
- Neoplasm Metastasis

## Interventions

- **DRUG:** Paclitaxel and Cisplatin
- **DRUG:** Cadonilimab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT06532539
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-13
- **Primary completion:** 2026-08
- **Final completion:** 2026-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06532539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06532539, "Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT06532539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*